ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma

Liu, Rui; Cheng, Qian; Kang, Liqing; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Zhang, Yi; Chu, Ling; Chen, Xin; Zhang, Chang; Tan, Jingwen; Xu, Nan; Li, Minghao; Yu, Lei; Li, Xin*new
Human Gene Therapy2022-3DOI: 10.1089/hum.2021.249
9被引4阅读
引用收藏
分享

摘要

Patients with central nervous system (CNS) lymphomas have a poor prognosis. Chimeric antigen receptor-modified (CAR) T cells have shown remarkable efficacy for B-cell non-Hodgkin's lymphoma. However, few studies have reported the effects of CAR T cells in the treatment of CNS lymphoma, and the duration of remission is short. In this study, seven CNS lymphoma patients (six patients with secondary CNS lymphomas and one patient with primary CNS lymphoma) were treated with CD19 or CD20 CAR T cell therapy, and the clinical efficacy and toxicity profiles were evaluated. All patients responded to CAR T cell therapy. Four patients achieved complete remission (CR), while three demonstrated partial remission. We also found that either CD19 or CD20 CAR T cells could be detected in the cerebrospinal fluid of four patients. The median progression-free survival and median overall survival were not assessed. The median duration of CR was 22.4 months. Five patients (5/7) in this cohort received combination therapy (bridging with autologous hematopoietic stem cell transplantation and programmed death-1 inhibitor for maintenance treatment) and three (3/7) received CAR T cell therapy as soon as possible after the relapse of CNS lymphoma. This could help explain why these patients achieved long-term remission. After a median follow-up of 10.4 months, three patients demonstrated disease progression, and the antigen loss of CD20 was confirmed as the reason for relapse in one patient. The results of this study suggest that CD19 or CD20 CAR T cells are effective against CNS lymphoma. This research was registered at http://www.chictr.org.cn (No. ChiCTR2000036350).

学科与关键词

关键词
CNS lymphomaCD19CD20chimeric antigen receptor-mediated T cellsantitumor effect
相关
加载中…
  • Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
    Zou, Rui; Zhou, Xiao; Liu, Hailing; Wang, Peng; Xia, Fan; Kang, Liqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*; Qu, Changju*Cancer Research and Treatment, 2023, 55(4): 1363-1368.被引 2
  • Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
    Qu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
  • Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement
    He, Bailin; Zhou, Hongsheng; Lin, Ren; Wang, Zhixiang; Xu, Na; Wang, Qiang; Sun, Jing; Liu, Xiaoli; Li, Peng; Liu, Qifa65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
查看全部 →

发表信息

论文状态
公开发表
期刊
Human Gene Therapy
发表日期
2022-03
卷期
第 33 卷, 第 5-6 期
页码
318-329
DOI
10.1089/hum.2021.249
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81870165, 82170204]; Natural Science Foundation of Hunan Province [2021JJ40916]

作者

  • L

    Liu, Rui (第一作者)

  • C

    Cheng, Qian

查看全部 16 位作者收起作者
  • K

    Kang, Liqing

  • W

    Wang, Erhua

  • L

    Li, Ying

  • Z

    Zhang, Jian

  • X

    Xiao, Han

  • Z

    Zhang, Yi

  • C

    Chu, Ling

  • C

    Chen, Xin

  • Z

    Zhang, Chang

  • T

    Tan, Jingwen

    new

  • X

    Xu, Nan

    new

  • L

    Li, Minghao

    new

  • Y

    Yu, Lei

    new

  • L

    Li, Xin (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417